About Fusion Antibodies
Fusion Antibodies is a company based in Belfast (United Kingdom) founded in 2001.. Fusion Antibodies has raised $2.5 million across 4 funding rounds from investors including Invest Northern Ireland, Crescent Capital and Qubis. Fusion Antibodies offers products and services including Antibody Humanization, Antibody Reformatting, Affinity Maturation, and Cell Line Development. Fusion Antibodies operates in a competitive market with competitors including SSI Strategy, August Research, ProductLife Group, Health Decisions and Phastar, among others.
- Headquarter Belfast, United Kingdom
- Stage Public
-
Sectors
Healthcare
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Fusion Antibodies Plc
-
Annual Revenue
$2.47 M (USD)72.98as on Mar 31, 2024
-
Net Profit
$-2.14 M (USD)23.05as on Mar 31, 2024
-
EBITDA
$-2.09 M (USD)18.66as on Mar 31, 2024
-
Total Equity Funding
$2.5 M (USD)
in 4 rounds
-
Latest Funding Round
$1.77 M (USD), Post-IPO
Feb 14, 2024
-
Investors
Invest Northern Ireland
& 3 more
-
Employee Count
Employee Count
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Fusion Antibodies
Fusion Antibodies is a publicly listed company on the LSE with ticker symbol FAB in UK, operating in the Health services sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of Fusion Antibodies
Fusion Antibodies offers a comprehensive portfolio of products and services, including Antibody Humanization, Antibody Reformatting, Affinity Maturation, and Cell Line Development. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Service for humanizing antibodies to reduce immunogenicity for therapeutics.
Process to reformat antibodies for improved functionality and production.
Technique to enhance antibody binding affinity for better efficacy.
Creation of stable cell lines for antibody production and testing.
Unlock access to complete
Funding Insights of Fusion Antibodies
Fusion Antibodies has successfully raised a total of $2.5M across 4 strategic funding rounds. The most recent funding activity was a Post-IPO round of $1.77 million completed in February 2024. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 4
- Last Round Post-IPO — $1.8M
-
First Round
First Round
(26 Jul 2007)
- Investors Count 4
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Feb, 2024 | Amount | Post-IPO - Fusion Antibodies | Valuation |
investors |
|
| Oct, 2020 | Amount | Grant - Fusion Antibodies | Valuation |
investors |
|
| Mar, 2018 | Amount | Grant - Fusion Antibodies | Valuation |
investors |
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Fusion Antibodies
Fusion Antibodies has secured backing from 4 investors, including institutional and venture fund investors. Prominent investors backing the company include Invest Northern Ireland, Crescent Capital and Qubis. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
-
|
Founded Year | Domain | Location | |
|
Qubis is engaged in commercializing academic research from Queen's University.
|
Founded Year | Domain | Location | |
|
-
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Fusion Antibodies
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Fusion Antibodies
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Fusion Antibodies Comparisons
Competitors of Fusion Antibodies
Fusion Antibodies operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as SSI Strategy, August Research, ProductLife Group, Health Decisions and Phastar, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Pharmacovigilance and medical affairs services are offered for drug development.
|
|
| domain | founded_year | HQ Location |
Clinical trial services are offered in Central and Eastern Europe.
|
|
| domain | founded_year | HQ Location |
Regulatory and pharmacovigilance support is provided for product lifecycles.
|
|
| domain | founded_year | HQ Location |
CRO focused on clinical trial services for data management, monitoring and biostatistics
|
|
| domain | founded_year | HQ Location |
Statistical consulting and data management for clinical trials are offered.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Fusion Antibodies
Frequently Asked Questions about Fusion Antibodies
When was Fusion Antibodies founded?
Fusion Antibodies was founded in 2001 and raised its 1st funding round 6 years after it was founded.
Where is Fusion Antibodies located?
Fusion Antibodies is headquartered in Belfast, United Kingdom. It is registered at Belfast, Northern Ireland, United Kingdom.
Who is the current CEO of Fusion Antibodies?
Adrian Kinkaid is the current CEO of Fusion Antibodies.
Is Fusion Antibodies a funded company?
Fusion Antibodies is a funded company, having raised a total of $2.5M across 4 funding rounds to date. The company's 1st funding round was a Grant of $21.38K, raised on Jul 26, 2007.
What is the annual revenue of Fusion Antibodies?
Annual revenue of Fusion Antibodies is $2.47M as on Mar 31, 2024.
What does Fusion Antibodies do?
Founded in 2001 and based in Belfast, United Kingdom, Fusion Antibodies operates as a contract research organization in the biotechnology sector. Services encompass antibody sequencing, humanization, stable cell line development, engineering, monoclonal antibody production, and transient protein expression. Two proprietary antibodies are currently in clinical and preclinical trials, supporting drug discovery and development processes.
Who are the top competitors of Fusion Antibodies?
Fusion Antibodies's top competitors include SSI Strategy, ProductLife Group and Health Decisions.
What products or services does Fusion Antibodies offer?
Fusion Antibodies offers Antibody Humanization, Antibody Reformatting, Affinity Maturation, and Cell Line Development.
Is Fusion Antibodies publicly traded?
Yes, Fusion Antibodies is publicly traded on LSE under the ticker symbol FAB.
Who are Fusion Antibodies's investors?
Fusion Antibodies has 4 investors. Key investors include Invest Northern Ireland, Crescent Capital, Qubis, and Viridian Investment Partners.
What is Fusion Antibodies's ticker symbol?
The ticker symbol of Fusion Antibodies is FAB on LSE.
Book a demo & talk to our team
Share a few details and we’ll reach out to schedule a session.